Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 2/13/2026

Guideline Recommendations for Evaluation and Management of a 1.5 cm Thyroid Nodule in Women

Initial Laboratory Evaluation

  • Serum TSH measurement is the single best initial laboratory test and must be obtained before any other work‑up in patients with a thyroid nodule. American College of Endocrinology / American Association of Clinical Endocrinologists recommendation. 1
  • When TSH is low or suppressed, free T4 and free T3 should be measured and a thyroid scintigraphy performed to identify an autonomously functioning (“hot”) nodule. American College of Endocrinology / American Association of Clinical Endocrinologists. 1
  • Suppressed TSH with a “hot” nodule indicates an almost universally benign lesion; biopsy is not indicated if no additional suspicious ultrasound features are present. American College of Endocrinology / American Association of Clinical Endocrinologists. 1
  • Elevated TSH warrants measurement of thyroid peroxidase antibodies and free T4 to evaluate for autoimmune thyroiditis. American College of Endocrinology / American Association of Clinical Endocrinologists. 1
  • Normal TSH permits direct progression to ultrasound risk stratification. American College of Endocrinology / American Association of Clinical Endocrinologists. 1

Ultrasound Assessment

  • High‑resolution thyroid ultrasound is mandatory for every woman with a palpable or suspected thyroid nodule and must be performed by a clinician experienced in thyroid sonography. American College of Endocrinology / American Association of Clinical Endocrinologists. 1
  • High‑risk ultrasound features that increase suspicion for malignancy include marked hypoechogenicity, irregular or spiculated margins, microcalcifications, taller‑than‑wide shape, and extrathyroidal extension. European Thyroid Association (EU‑TIRADS). 2

Risk Stratification (EU‑TIRADS)

EU‑TIRADS Category Typical Ultrasound Findings Approximate Malignancy Risk FNA Recommendation for a 15 mm Nodule
5 (high suspicion) ≥ one high‑risk feature 26 % – 87 % Mandatory FNA (size threshold ≥10 mm)
4 (intermediate) Mildly hypoechoic, no high‑risk feature 6 % – 17 % Recommended FNA if >10 mm and not definitively benign
3 (low suspicion) Isoechoic, no high‑risk feature 2 % – 4 % Not indicated at 15 mm; biopsy only if >20 mm
2 (very low) Anechoic or spongiform ≈ 0 % Not indicated at any size unless progressive enlargement
1 (benign) Pure cystic 0 % No biopsy required

The malignancy risk estimates and FNA thresholds are derived from the *European Thyroid Association (EU‑TIRADS) guidelines. 2

Fine‑Needle Aspiration (FNA) Indications

  • For nodules classified as EU‑TIRADS 5, FNA is mandatory at any size ≥10 mm. European Thyroid Association together with American College of Endocrinology / American Association of Clinical Endocrinologists. [2][1]
  • For EU‑TIRADS 4 nodules, FNA is recommended for lesions >10 mm that lack a definitively benign appearance. European Thyroid Association together with American College of Endocrinology / American Association of Clinical Endocrinologists. [2][1]
  • EU‑TIRADS 3 nodules do not require FNA at 15 mm; the biopsy threshold is >20 mm. European Thyroid Association together with American College of Endocrinology / American Association of Clinical Endocrinologists. [2][1]
  • EU‑TIRADS 2 nodules are not biopsied at any size unless there is documented progressive growth. European Thyroid Association together with American College of Endocrinology / American Association of Clinical Endocrinologists. [2][1]

Special Situations

  • Presence of suspicious cervical lymph nodes (e.g., loss of fatty hilum, rounded shape, microcalcifications) mandates FNA of both the thyroid nodule and the lymph node with thyroglobulin measurement in the washout, irrespective of nodule size. European Thyroid Association. 2
  • A personal or family history of thyroid cancer, prior head/neck irradiation, or hereditary cancer syndromes (e.g., Cowden, MEN 2, DICER1) lowers the FNA size threshold and warrants biopsy even for smaller lesions. American College of Endocrinology / American Association of Clinical Endocrinologists. 1
  • Functioning (“hot”) nodules identified on scintigraphy should not be biopsied, even if ultrasound shows high‑risk features, because malignancy is exceedingly rare. American College of Endocrinology / American Association of Clinical Endocrinologists. 1

FNA Technique (When Indicated)

  • Ultrasound‑guided FNA is mandatory; palpation‑guided attempts have unacceptably high nondiagnostic rates. American College of Endocrinology / American Association of Clinical Endocrinologists. 1
  • Use 23–27 gauge needles and obtain samples from at least two distinct sites within the nodule to improve diagnostic yield. American College of Endocrinology / American Association of Clinical Endocrinologists. 1
  • Cytology should be reported using the Bethesda System (categories I–VI) to standardize management decisions. American College of Endocrinology / American Association of Clinical Endocrinologists. 1

Management Pitfalls to Avoid

  • Skipping the initial TSH measurement is prohibited because TSH determines whether scintigraphy is required. American College of Endocrinology / American Association of Clinical Endocrinologists. 1
  • Do not biopsy nodules <10 mm unless they exhibit high‑risk ultrasound features and additional risk factors (suspicious lymph nodes, extrathyroidal extension, high‑risk personal/family history). European Thyroid Association together with American College of Endocrinology / American Association of Clinical Endocrinologists. [2][1]
  • Do not biopsy “hot” nodules identified on scintigraphy when TSH is suppressed, as they are almost always benign. American College of Endocrinology / American Association of Clinical Endocrinologists. 1
  • Levothyroxine suppression therapy is not recommended for benign nodules in euthyroid patients; it offers no benefit and increases the risk of atrial fibrillation and bone loss. American College of Endocrinology / American Association of Clinical Endocrinologists. 1

Clinical Examination and Initial Work‑up of Thyroid Nodules

History Taking

  • Elicit family history of thyroid disease, especially medullary thyroid carcinoma associated with multiple endocrine neoplasia type 2. 3
  • Ask about prior neck or supraclavicular radiation exposure, which raises the risk of thyroid pathology. 3
  • Screen for hereditary cancer syndromes that increase thyroid cancer risk (e.g., Cowden, Carney, familial adenomatous polyposis/Gardner, Werner, DICER1). 3
  • Record patient demographics (age, gender) and special populations (children, pregnant women, elderly, patients with significant comorbidities). 3
  • Document the onset and evolution of thyroid‑related symptoms (e.g., neck mass, dysphagia, voice change). 3

Physical Examination – Core Components

Inspection

  • Look for thyroid enlargement or asymmetry, which may indicate goiter or focal disease. 3
  • Observe collateral neck veins; dilated veins suggest venous compression by an enlarged gland. 3
  • Perform Pemberton’s sign (facial plethora and neck vein distension on arm elevation) to detect substernal extension of a goiter. 3

Palpation of the Thyroid Gland

  • Systematically assess gland volume, pain on palpation, and consistency (soft, firm, hard). 3

Nodule Characterization (if palpable)

  • Measure size of each nodule. 3
  • Note topography (location within the gland). 3
  • Evaluate border regularity; irregular margins raise suspicion. 3
  • Assess hardness; a firm‑to‑hard texture is a malignancy cue. 3
  • Test mobility; fixation to surrounding structures suggests invasive disease. 3
  • Count number of nodules (solitary vs. multiple). 3

Cervical Lymph‑Node Examination

  • Palpate all cervical lymph‑node regions bilaterally; the presence of abnormal nodes points toward possible metastatic thyroid cancer. 4

Assessment for Compressive Symptoms

  • Inquire about voice changes (hoarseness) indicating recurrent laryngeal nerve involvement. 3
  • Ask about dysphagia (difficulty swallowing) that may reflect extrinsic compression. 3
  • Evaluate for inspiratory or positional laryngeal dyspnea, which can signal airway compromise. 3

Functional Assessment

  • Identify symptoms of hyperthyroidism (e.g., weight loss, tremor). 3
  • Identify symptoms of hypothyroidism (e.g., fatigue, cold intolerance). 3

Red‑Flag Clinical Signs Suggestive of Malignancy

  • Rapid, asymmetric growth of a thyroid nodule. 3
  • Large, firm‑to‑hard, irregular nodule adherent to adjacent tissues. 3
  • New‑onset dysphonia from tumor infiltration of the recurrent laryngeal nerve. 3
  • Persistent dysphagia unrelated to benign causes. 3
  • Positional laryngeal dyspnea that worsens with neck extension or lying down. 3

Initial Laboratory and Imaging Recommendations (American College of Endocrinology & American Association of Clinical Endocrinologists)

  • Obtain a serum TSH measurement as the first laboratory test for any patient with a palpable thyroid nodule or relevant risk factors. 4
  • Perform thyroid ultrasonography by a clinician experienced in thyroid sonography to characterize nodules and guide further management. 4

REFERENCES

← Return to Home